Advertisement
Screener

Skye Bioscience, Inc. (SKYE) Increase (Decrease) in Accounts Receivable

2.8 / 5 stars · 68/120 Roast Me

Skye Bioscience, Inc. Increase (Decrease) in Accounts Receivable

Skye Bioscience, Inc. (SKYE) reported Increase (Decrease) in Accounts Receivable of $1.19 thousand for the 9-month period ending 2014-07-31, per its 10-Q filed 2014-09-15.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2014-09-15

  • Skye Bioscience, Inc. increase (decrease) in accounts receivable for the quarter ending 2014-07-31 was -$8.90K.
  • Skye Bioscience, Inc. increase (decrease) in accounts receivable for the quarter ending 2014-04-30 was $623.00, a 94.04% decline year-over-year.
  • Skye Bioscience, Inc. increase (decrease) in accounts receivable for the quarter ending 2014-01-31 was $9.46K, a 35.73% decline year-over-year.
  • Skye Bioscience, Inc. increase (decrease) in accounts receivable for the quarter ending 2013-10-31 was -$3.33K.
  • Skye Bioscience, Inc. increase (decrease) in accounts receivable for fiscal 2013 was $18.43K, a 166.90% increase from fiscal 2012.
  • Skye Bioscience, Inc. increase (decrease) in accounts receivable for fiscal 2012 was $6.91K.
Period endIncrease (Decrease) in Accounts Receivable 3 monthIncrease (Decrease) in Accounts Receivable 6 monthIncrease (Decrease) in Accounts Receivable 6 month as first filedIncrease (Decrease) in Accounts Receivable 9 monthIncrease (Decrease) in Accounts Receivable 12 monthIncrease (Decrease) in Accounts Receivable 25 monthIncrease (Decrease) in Accounts Receivable 29 month
2014-07-31-$8.90K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-09-15
-$8.27K
derived: sum of 2 quarters · filed 2014-09-15
$1.19K
10-Q · filed 2014-09-15
-$2.14K
derived: sum of 4 quarters · filed 2014-09-15
2014-04-30$623.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-06-05
$10.09K
10-Q · filed 2014-06-05
$6.76K
derived: sum of 3 quarters · filed 2014-06-05
$3.35K
derived: sum of 4 quarters · filed 2014-09-15
2014-01-31$9.46K
10-Q · filed 2014-03-17
$6.14K
derived: sum of 2 quarters · filed 2014-03-17
$2.72K
derived: sum of 3 quarters · filed 2014-09-15
$13.17K
derived: sum of 4 quarters · filed 2014-09-15
2013-10-31-$3.33K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-01-27
-$6.74K
derived: sum of 2 quarters · filed 2014-09-15
$3.71K
derived: sum of 3 quarters · filed 2014-09-15
$18.43K
10-K · filed 2014-01-27
2013-07-31-$3.41K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-09-15
$7.03K
derived: sum of 2 quarters · filed 2014-09-15
$21.76K
10-Q · filed 2014-09-15
$28.67K
10-Q · filed 2013-09-16
2013-04-30$10.45K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-06-05
$25.17K
10-Q · filed 2014-06-05
-$25.17K
10-Q · filed 2013-06-27
-$32.08K
10-Q · filed 2013-06-27
2013-01-31$14.73K
10-Q · filed 2014-03-17
2012-10-31$6.91K
10-K · filed 2014-01-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
CalciMedica, Inc. (CALC)United States$0.061B-1.42
TALPHERA, INC. (TLPH)United States$0.060B
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Rein Therapeutics, Inc. (RNTX)United States$0.063B-1.76
HYPERION DEFI, INC. (HYPD)United States$0.065B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
XBiotech Inc. (XBIT)United States$0.066B-1.56
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38
Clene Inc. (CLNN)United States$0.054B-1.99